Tryptamine Therapeutics (ASX:TYP) has reached another critical milestone in its program to treat Binge Eating Disorder (BED), confirming the enrolment of a second participant in its clinical trial of TRP-8803, an intravenous formulation of psilocin. …
Tryp advances psilocin trial for binge eating disorder as second patient enrolled
November 18, 2025 Australian Biotech
Latest Video
New Stories
-
What is it with this organisation's obsession with pharmacy and Europe?
July 13, 2026 - - Latest News -
Mesoblast reports strong cell therapy revenue as first year as uptake grows
July 13, 2026 - - Latest News -
The inevitability of disappointment over a reform process that has devolved into word games
July 12, 2026 - - Latest News -
The 'Dispatched' Podcast - Series 5, Ep 23
July 10, 2026 - - Podcast -
Disruption is the overdue remedy and how this debate can revitalise the PBS
July 10, 2026 - - Latest News -
Melbourne study links higher tumour radiation dose to longer progression-free survival
July 10, 2026 - - Latest News -
Older Australians are underestimating their personal risk from RSV
July 10, 2026 - - Latest News